Atrium Health Union
- Type
- Teaching hospital
- Where
- Monroe, NC
- Medicare CCN
- 340130
- Received
- $8,065,030 in 395 records, 2022 ($908,141 general, $7,156,888 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 32 | $908,141 |
| 2022 | Research payment | 363 | $7,156,888 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 363 | $7,156,888 |
| Consulting Fee | 5 | $471,982 |
| Grant | 2 | $237,302 |
| Space rental or facility fees (teaching hospital only) | 14 | $127,243 |
| Long term medical supply or device loan | 9 | $28,461 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $25,000 |
| Debt forgiveness | 1 | $18,152 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Gilead Sciences, Inc. | $236,302 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $14,118 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,681 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $11,642 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,095 | Research payment | In-kind items and services | RECARBRIO Drug, INFECTIOUS DISEASE | An observation study comparing prospective use of Imipenem,Cilastatin,Relebactam IMI,REL to retrospective data using Mer | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,860 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | Stryker Corporation | $4,811 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2022 | |
| 2022-12-31 | Stryker Corporation | $4,750 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2022 | |
| 2022-12-31 | Stryker Corporation | $4,750 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,360 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,125 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,866 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,807 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,109 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2022 |
| 2022-12-31 | Stryker Corporation | $2,760 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $2,696 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic | 2022 |
| 2022-12-31 | Stryker Corporation | $2,557 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2022 | |
| 2022-12-31 | Stryker Corporation | $2,443 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2022 | |
| 2022-12-31 | Stryker Corporation | $2,443 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,369 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2022 |
| 2022-12-31 | Stryker Corporation | $1,972 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2022 | |
| 2022-12-31 | Stryker Corporation | $1,972 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,902 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,107 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $951 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck S | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $121 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Epacadostat or Placebo in Combination With Pembrolizumab | 2022 |
| 2022-12-27 | Edwards Lifesciences Corporation | $1,792 | Research payment | Cash or cash equivalent | The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study (2016-05) | 2022 | |
| 2022-12-22 | SEAGEN INC. | $27,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase 1b Dose Escalation Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy for HER | 2022 |
| 2022-12-22 | Edwards Lifesciences Corporation | $400 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2022 | |
| 2022-12-21 | GLOBAL BLOOD THERAPEUTICS, INC. | $9,085 | Research payment | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | AN OPEN LABEL, OBSERVATIONAL, PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE (SCD) TREATED WITH OXBRYTA ( | 2022 |
| 2022-12-16 | Immedica Pharma US, Inc. | $1,512 | Research payment | Cash or cash equivalent | RAISE | 2022 | |
| 2022-12-15 | E.R. Squibb & Sons, L.L.C. | $64,681 | Research payment | Cash or cash equivalent | EMPLICITI Biological, Oncology | Phase II Study of Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed Multiple Myeloma | 2022 |
| 2022-12-15 | Janssen Research & Development, LLC | $20,401 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2022 |
| 2022-12-14 | Intercept Pharmaceuticals, Inc. | $8,079 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-12-14 | Intercept Pharmaceuticals, Inc. | $4,341 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-12-12 | Merck Sharp & Dohme LLC | $95,492 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-09 | Penumbra, Inc. | $3,923 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
| 2022-12-09 | Penumbra, Inc. | $541 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
| 2022-12-08 | Edwards Lifesciences Corporation | $46,470 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2022 | |
| 2022-12-06 | PFIZER INC. | $5,363 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-12-05 | E.R. Squibb & Sons, L.L.C. | $2,301 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIB Multi Tumor (Viral Mediated) | 2022 |
| 2022-12-01 | Pharmacyclics LLC, an AbbVie Company | $3,566 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2022 |
| 2022-12-01 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-12-01 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-12-01 | Pharmacyclics LLC, an AbbVie Company | $43 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-11-30 | Edwards Lifesciences Corporation | $2,377 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2022 | |
| 2022-11-30 | E.R. Squibb & Sons, L.L.C. | $1,056 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Study Adj GEJ & Esoph (US EU) (mono) - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Ni | 2022 |
| 2022-11-29 | E.R. Squibb & Sons, L.L.C. | $828 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase I/II PK/Safety in Adj Melanoma w New Cell Line | 2022 |
| 2022-11-28 | Janssen Research & Development, LLC | $27,000 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2022 | |
| 2022-11-28 | Janssen Research & Development, LLC | $27,000 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2022 | |
| 2022-11-28 | Incyte Corporation | $6,780 | Research payment | Cash or cash equivalent | Noninterventional Epigenomic Mapping of CD34 plus Cells From Healthy Participants and Patients With Myelofibrosis (MF) a | 2022 | |
| 2022-11-25 | Janssen Research & Development, LLC | $56,595 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2022 |
| 2022-11-25 | Janssen Research & Development, LLC | $20,000 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2022 |
| 2022-11-25 | Edwards Lifesciences Corporation | $19,297 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2022 | |
| 2022-11-25 | Edwards Lifesciences Corporation | $9,500 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-11-22 | NuVasive, Inc. | $7,992 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | 2022 | |
| 2022-11-21 | PFIZER INC. | $10,502 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | WI211002 PILOT TRIAL OF ANASTROZOLE AND PALBOCICLIB AS FIRSTLINE THERAPY AND AS MAINTENANCE THERAPY AFTER FIRSTLINE CHEM | 2022 |
| 2022-11-21 | E.R. Squibb & Sons, L.L.C. | $1,200 | Research payment | Cash or cash equivalent | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | 2022 | |
| 2022-11-21 | E.R. Squibb & Sons, L.L.C. | $729 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B/C Opdivo Mono | 2022 |
| 2022-11-16 | E.R. Squibb & Sons, L.L.C. | $22,920 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase I/IIA 2L/3L CRC MSS KRAS Nivo/MEK Combo (trametinib/Novartis) | 2022 |
| 2022-11-16 | Immedica Pharma US, Inc. | $1,450 | Research payment | Cash or cash equivalent | RAISE | 2022 | |
| 2022-11-15 | Alnylam Pharmaceuticals Inc. | $180 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2022 |
| 2022-11-11 | PFIZER INC. | $26,931 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-11-10 | E.R. Squibb & Sons, L.L.C. | $180 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III MEL 1L, PD-1 vs Ipi vs. PD-1+Ipi - A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivol | 2022 |
| 2022-11-09 | Intercept Pharmaceuticals, Inc. | $4,336 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-11-07 | E.R. Squibb & Sons, L.L.C. | $1,350 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III RCC 1L Combo - A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib | 2022 |
| 2022-11-07 | E.R. Squibb & Sons, L.L.C. | $569 | Research payment | Cash or cash equivalent | Ph II/III IO Naive Mel (lag3 + nivo FDC) - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolu | 2022 | |
| 2022-11-01 | USWM, LLC | $291,412 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-01 | NuVasive, Inc. | $12,115 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | 2022 | |
| 2022-11-01 | USWM, LLC | $11,973 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-10-31 | Merck Sharp & Dohme LLC | $214,149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2022 |
| 2022-10-26 | Edwards Lifesciences Corporation | $1,837 | Research payment | Cash or cash equivalent | The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study (2016-05) | 2022 | |
| 2022-10-20 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-10-20 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-10-20 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-10-20 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-10-19 | Intercept Pharmaceuticals, Inc. | $10,653 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-10-18 | Immedica Pharma US, Inc. | $5,300 | Research payment | Cash or cash equivalent | RAISE | 2022 | |
| 2022-10-14 | Penumbra, Inc. | $1,389 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
| 2022-10-13 | Stryker Corporation | $9,523 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL | 2022 | |
| 2022-10-13 | PFIZER INC. | $2,600 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-10-07 | SEAGEN INC. | $185,500 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin | 2022 |
| 2022-10-05 | PFIZER INC. | $3,708 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-10-04 | Edwards Lifesciences Corporation | $1,854 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2022 | |
| 2022-10-04 | Edwards Lifesciences Corporation | $1,512 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2022 | |
| 2022-09-30 | PFIZER INC. | $30,608 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-09-30 | Edwards Lifesciences Corporation | $4,038 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2022 | |
| 2022-09-29 | PFIZER INC. | $16,073 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-09-29 | Janssen Research & Development, LLC | $132 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2022 |
| 2022-09-26 | Janssen Research & Development, LLC | $298 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-09-23 | PFIZER INC. | $33,608 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-09-23 | Janssen Research & Development, LLC | $9,678 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-09-22 | Janssen Research & Development, LLC | $80,121 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-09-22 | UROVANT SCIENCES INC | $2,000 | Research payment | Cash or cash equivalent | An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge | 2022 | |
| 2022-09-22 | UROVANT SCIENCES INC | $700 | Research payment | Cash or cash equivalent | An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge | 2022 | |
| 2022-09-22 | UROVANT SCIENCES INC | $500 | Research payment | Cash or cash equivalent | An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge | 2022 | |
| 2022-09-21 | GLOBAL BLOOD THERAPEUTICS, INC. | $5,758 | Research payment | Cash or cash equivalent | OXBRYTA Drug, Sickle Cell Disease | AN OPEN LABEL, OBSERVATIONAL, PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE (SCD) TREATED WITH OXBRYTA ( | 2022 |
| 2022-09-19 | Gilead Sciences, Inc. | $12,855 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2022 |
| 2022-09-14 | Intercept Pharmaceuticals, Inc. | $29,513 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-14 | Intercept Pharmaceuticals, Inc. | $29,513 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-14 | Intercept Pharmaceuticals, Inc. | $6,158 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-14 | Intercept Pharmaceuticals, Inc. | $6,158 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-14 | SEAGEN INC. | $1,537 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-09-14 | SEAGEN INC. | $796 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-09-14 | SEAGEN INC. | $253 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-09-14 | SEAGEN INC. | $253 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-09-12 | Penumbra, Inc. | $2,634 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
| 2022-09-10 | PFIZER INC. | $11,000 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-09-09 | Pharmacyclics LLC, an AbbVie Company | $1,783 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2022 |
| 2022-09-09 | Edwards Lifesciences Corporation | $295 | Research payment | Cash or cash equivalent | Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial #2018-02 | 2022 | |
| 2022-09-07 | Intercept Pharmaceuticals, Inc. | $6,792 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-07 | Intercept Pharmaceuticals, Inc. | $6,792 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-09-07 | Pharmacyclics LLC, an AbbVie Company | $1,783 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2022 |
| 2022-09-06 | Janssen Research & Development, LLC | $33,058 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2022 |
| 2022-09-02 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NINLARO Drug, ONCOLOGY | 2022 | |
| 2022-09-02 | Celgene Corporation | $21,485 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) | 2022 |
| 2022-09-02 | Janssen Research & Development, LLC | $132 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2022 |
| 2022-08-29 | PFIZER INC. | $10,502 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PILOT TRIAL OF ANASTROZOLE AND PALBOCICLIB AS FIRSTLINE THERAPY AND AS MAINTENANCE THERAPY AFTER FIRSTLINE CHEMOTHERAPY | 2022 |
| 2022-08-29 | Janssen Research & Development, LLC | $2,225 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2022 |
| 2022-08-28 | AstraZeneca Pharmaceuticals LP | $25,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-08-26 | Janssen Research & Development, LLC | $894 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2022 |
| 2022-08-25 | Janssen Research & Development, LLC | $60,483 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-08-25 | Edwards Lifesciences Corporation | $20,384 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2022 | |
| 2022-08-25 | Janssen Research & Development, LLC | $9,638 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-08-24 | SEAGEN INC. | $103,486 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin | 2022 |
| 2022-08-23 | PFIZER INC. | $72 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-22 | SEAGEN INC. | $185,500 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin | 2022 |
| 2022-08-22 | Regeneron Pharmaceuticals, Inc. | $11,529 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FO | 2022 | |
| 2022-08-19 | ABBVIE INC. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-08-19 | Alnylam Pharmaceuticals Inc. | $2,000 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of | 2022 |
| 2022-08-17 | AstraZeneca Pharmaceuticals LP | $5,188 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2022 |
| 2022-08-17 | Intercept Pharmaceuticals, Inc. | $3,314 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-08-17 | Intercept Pharmaceuticals, Inc. | $2,209 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-08-16 | PFIZER INC. | $11,944 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-13 | PFIZER INC. | $2,005 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-08-12 | Alexion Pharmaceuticals, Inc. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Biological, Rare Disease | 2022 | |
| 2022-08-10 | Intercept Pharmaceuticals, Inc. | $9,302 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-08-10 | PFIZER INC. | $6,384 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-10 | Gilead Sciences, Inc. | $5,500 | Research payment | Cash or cash equivalent | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 | |
| 2022-08-10 | Intercept Pharmaceuticals, Inc. | $5,236 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-08-10 | Intercept Pharmaceuticals, Inc. | $2,878 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-08-10 | Edwards Lifesciences Corporation | $2,777 | Research payment | Cash or cash equivalent | The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study (2016-05) | 2022 | |
| 2022-08-10 | Intercept Pharmaceuticals, Inc. | $1,440 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-08-10 | Penumbra, Inc. | $655 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
| 2022-08-05 | Janssen Research & Development, LLC | $800 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2022 |
| 2022-08-03 | PFIZER INC. | $51,338 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-08-03 | Intercept Pharmaceuticals, Inc. | $24,389 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-08-03 | Intercept Pharmaceuticals, Inc. | $7,500 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-08-03 | Intercept Pharmaceuticals, Inc. | $4,950 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-07-28 | PFIZER INC. | $16,541 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-07-28 | Epizyme, Inc. | $8,558 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO I | 2022 |
| 2022-07-27 | Intercept Pharmaceuticals, Inc. | $8,635 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2022 | |
| 2022-07-27 | PFIZER INC. | $1,950 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2022 | |
| 2022-07-25 | Janssen Research & Development, LLC | $48,054 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-07-25 | Janssen Research & Development, LLC | $10,263 | Research payment | Cash or cash equivalent | A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for | 2022 | |
| 2022-07-20 | SEAGEN INC. | $92,750 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin | 2022 |
| 2022-07-20 | Intercept Pharmaceuticals, Inc. | $5,371 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-07-20 | Intercept Pharmaceuticals, Inc. | $3,869 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-07-19 | AstraZeneca Pharmaceuticals LP | $81,378 | Research payment | Cash or cash equivalent | A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI22 | 2022 | |
| 2022-07-14 | Pharmacyclics LLC, an AbbVie Company | $6,142 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | 2022 |
| 2022-07-14 | Edwards Lifesciences Corporation | $4,692 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-07-13 | SEAGEN INC. | $4,611 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $2,003 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $2,003 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $796 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $796 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $796 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $682 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $682 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $682 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-13 | SEAGEN INC. | $682 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2022 |
| 2022-07-12 | Janssen Research & Development, LLC | $16,500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2022 |
| 2022-07-11 | Janssen Research & Development, LLC | $121,042 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2022 | |
| 2022-07-11 | Edwards Lifesciences Corporation | $926 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2022 | |
| 2022-07-08 | Janssen Research & Development, LLC | $4,550 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone DRVd Versus Lenalido | 2022 |
| 2022-07-08 | Janssen Research & Development, LLC | $4,547 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Phase 2 Randomized Open Label Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone DRVd Versus Lenalido | 2022 |
| 2022-07-07 | Alexion Pharmaceuticals, Inc. | $5,682 | Research payment | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | A Phase 3, Open Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome | 2022 |
| 2022-07-07 | Edwards Lifesciences Corporation | $1,455 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2022 | |
| 2022-07-07 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-07-06 | Penumbra, Inc. | $2,219 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
| 2022-07-06 | Intercept Pharmaceuticals, Inc. | $1,156 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-07-05 | Edwards Lifesciences Corporation | $58,890 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2022 | |
| 2022-07-02 | PFIZER INC. | $96,660 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-07-01 | USWM, LLC | $148,857 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-01 | USWM, LLC | $14,740 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-01 | USWM, LLC | $5,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-01 | Janssen Research & Development, LLC | $132 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2022 |
| 2022-06-30 | PFIZER INC. | $4,354 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2022 |
| 2022-06-28 | PFIZER INC. | $6,015 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-06-27 | PFIZER INC. | $210,051 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PILOT TRIAL OF ANASTROZOLE AND PALBOCICLIB AS FIRSTLINE THERAPY AND AS MAINTENANCE THERAPY AFTER FIRSTLINE CHEMOTHERAPY | 2022 |
| 2022-06-27 | Janssen Research & Development, LLC | $30,304 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-06-22 | Intercept Pharmaceuticals, Inc. | $5,833 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-06-22 | Intercept Pharmaceuticals, Inc. | $2,823 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-06-21 | Janssen Research & Development, LLC | $98,415 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2022 | |
| 2022-06-20 | SEAGEN INC. | $185,500 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin | 2022 |
| 2022-06-16 | ABBVIE INC. | $16,075 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participa | 2022 |
| 2022-06-16 | E.R. Squibb & Sons, L.L.C. | $3,432 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph IIIB Dose Comparison N3 I1 vs I3 N1 in melanoma | 2022 |
| 2022-06-16 | Penumbra, Inc. | $1,009 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2022 |
The latest 200 records of 395.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Monroe, NC, county Union County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Monroe, NC | County Union County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 36,759 | 250,958 | 10,730,404 |
| Population, 2020 census P1 | 34,562 | 238,267 | 10,439,388 |
| Median age B01002 | 35.5 | 39.2 | 39.1 |
| Under 18 B01001 | 24.5% | 25.6% | 21.8% |
| 65 and over B01001 | 14.9% | 13.5% | 17.2% |
| Households B11001 | 12,620 | 84,237 | 4,282,345 |
| Foreign born B05002 | 17.8% | 12.2% | 9.1% |
| Median household income B19013 | $72,540 | $102,900 | $72,388 |
| Median family income B19113 | $80,817 | $118,218 | $90,290 |
| Per capita income B19301 | $31,089 | $46,949 | $41,385 |
| Poverty rate B17001 | 13.3% | 7.7% | 13.0% |
| Unemployment rate B23025 | 4.6% | 4.2% | 4.7% |
| Civilian labor force B23025 | 18,613 | 132,592 | 5,336,863 |
| Mean commute (minutes) B08013 | 30.1 | 29.8 | 25.1 |
| Bachelor's degree or higher B15003 | 24.1% | 40.5% | 35.7% |
| Housing units B25001 | 13,469 | 88,851 | 4,895,668 |
| Owner-occupied B25003 | 61.6% | 81.6% | 66.6% |
| Renters B25003 | 38.4% | 18.4% | 33.4% |
| Median home value B25077 | $309,100 | $417,300 | $288,900 |
| Median gross rent B25064 | $1,246 | $1,496 | $1,228 |
| White, not Hispanic B03002 | 43.7% | 66.8% | 60.0% |
| Black B03002 | 19.7% | 10.9% | 20.0% |
| Hispanic or Latino B03002 | 30.9% | 13.4% | 11.3% |
| Asian B03002 | 1.0% | 4.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Monroe, NC.
Comments